Did the removal of the indication of nocturnal enuresis for intranasal desmopressin change prescribing practice?

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 1, 2011, Pages 105-109

  Hoffmann, Falk ^a   Glaeske, Gerd ^a   Steuber, Christian ^b  

^a UNIVERSITY OF BREMEN   (Germany)

^b Klinikum Links der Weser   (Germany)

Author keywords

Children; Desmopressin; Formulations; Germany; Urinary incontinence

Indexed keywords

DESMOPRESSIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL DECISION MAKING; CLINICAL PRACTICE; FEMALE; GENERAL PRACTITIONER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NOCTURNAL ENURESIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; URINE INCONTINENCE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADOLESCENT; ANTIDIURETIC AGENTS; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FEMALE; GERMANY; HUMANS; INFANT; MALE; NOCTURNAL ENURESIS; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; URINARY INCONTINENCE;

EID: 78650377200     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2070     Document Type: Article

References (15)

1. Butler RJ, Heron J. The prevalence of infrequent bedwetting and nocturnal enuresis in childhood. A large British cohort. Scand J Urol Nephrol 2008; 42(3): 257-264.
2. Robson WL. Clinical practice. Evaluation and management of enuresis. N Engl J Med 2009; 360(14): 1429-1436.
3. Glazener CMA, Evans JHC. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2002; (3): Art. No.: CD002112
4. Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, Müller D. Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors? J Urol 2005; 174(1): 294-298.
5. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol 2007; 178(1): 24-30.
6. Van de Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis? A focus on safety issues. Drug Saf 2010; 33(4): 261-271.
7. FDA. Information for Healthcare Professionals: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray). FDA ALERT [12/4/2007], 2007. Available at: (last accessed on July 28, 2010).
8. BfArM. Desmopressin Nasenspray und das Risiko von Hyponatriämie und Wasserintoxikation; Streichung der Indikation primäre Enuresis nocturna (PNE). 2007. Available at: (last accessed on July 28, 2010).
9. Gleason PP, Walters C, Heaton AH, Schafer JA. Telithromycin: the perils of hasty adoption and persistence of off- label prescribing. J Manag Care Pharm 2007; 13(5): 420-425.
10. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk- warning events. J Manag Care Pharm 2008; 14(6): 523-531.
11. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000; 284(23): 3036-3039.
12. Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Off- label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2008; 2(1): 24.
13. Butler RJ, Golding J, Heron J. ALSPAC Study Team. Nocturnal enuresis: a survey of parental coping strategies at 71/2 years. Child Care Health Dev 2005; 31(6): 659-667.
14. Bower WF, Moore KH, Shepherd RB, Adams RD. The epidemiology of childhood enuresis in Australia. Br J Urol 1996; 78(4): 602-606.
15. KBV. Grunddaten 2008/2009 zur vertragsärztlichen Versorgung in Deutschland. Ärzte, Stand: 31.12.2008, 2008; (last accessed on July 28, 2010).